Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Neuralstem: An Update on Its Pipeline and Supporting Clinical Trials (CUR, Neutral, $1.00)

Purpose of this Report
Neuralstem has been silent for nearly three months on when the critical phase 2b trial of its…
Read more…

Neuralstem: My Analysis of Phase 1 and Phase 2 Results for NSI-566 Neural Stem Cells in ALS Indicates Encouraging Signals of Efficacy (CUR, Buy, $1.25)

Putting This Report in Perspective†

This is an extensive report that goes over the aggregate results of the phase 1 and…
Read more…

Neuralstem: A Closer Look at Encouraging Phase 2 Results for NSI-566 Neural Stem Cells in Treating ALS (CUR, Buy, $2.36)

Observations about the Phase 2 Trial Results

I spent the weekend thinking about the data released in the phase 2 trial…
Read more…

Neuralstem: When Will We See the Phase 2 Data for NSI-566 in ALS? (CUR, Buy, $3.75)

Management has guided that the phase 2 data on 15 patients treated in the phase 2 trial of NSI-566 neural…
Read more…

Notes from Neuralstem Presentation at Biotech Showcase Conference, January 13, 2015 (CUR, Buy, $3.09)

Richard Gar, CEO of Neuralstem (CUR), made a presentation at Biotech Showcase Conference in San Francisco on January 13, 2015.…
Read more…

Neuralstem: An Update on Potential Catalysts for 2015 (CUR, Buy, 3.38)

Overview and Investment Thinking

I wrote a report on Neuralstem on August 26, 2014†in which I projected the timing of important…
Read more…

Weakness in Neuralstem Caused by Seeking Alpha Article Presents a Buying Opportunity (CUR, $2.69, Buy)

This is an updated version of a blog that was published on October 20th.
A Seeking Alpha article on results from…
Read more…

Neuralstem: Previewing Upcoming Important Events and Some Thoughts on the StemCell Patent Infringement Lawsuit (CUR, $3.62 Buy, August 26, 2014)

Key Points

The phase 2 trial of NSI-566 in 15 ALS patients has completed enrollment (surgeries) and final topline data could…
Read more…

Neuralstem: Phase 1b Results for NSI-189 are Very Encouraging but It Is Early Days (CUR, Buy, $4.38, For paid subscribers)

Investment Thesis on Neuralstem

I continue with my long standing buy on Neuralstem that is almost entirely based on the potential…
Read more…

Neuralstem: Encouraging Phase 1b Data on NSI-189 (CUR, Buy, $4.35, Free content)

On June 17 at the American Society of Clinical Psychopharmacology Neuralstem reported phase 1b data for its small molecule drug…
Read more…

Neuralstem: An In-Depth Look at NSI-189, A Novel Small Molecule Drug Being Studied in Major Depressive Disorder (CUR, Buy, $3.60, For Paid Subscribers)

Investment Thesis

My recommendation of Neuralstem (CUR) has been based primarily on the potential for its neural stem cells NSI-566 in…
Read more…

Thoughts on the Market Correction in Biotechnology Stocks

This Has Been a Tough Correction

The recent sharp market correction and rotation out of growth stocks like biotechnology and technology…
Read more…

Neuralstem: Dr. Eva Feldmanís Latest Presentation on The Use of CURís Stem Cells in ALS (CUR, Buy, $4.04)

Overview
Dr. Eva Feldman is the lead investigator for the clinical trials of Neuralstemís (CUR) NSI-566 spinal cord stem cells in…
Read more…

Neuralstem (CUR, Buy, $4.48) Publishing of Phase 1 Results in Annals of Neurology Causes Price Surge (Paid Subscribers Only)

Introduction

The final results of the phase 1 trial of Neuralstemís (CUR) NSI-566 spinal cord stem cells in the treatment of…
Read more…

Chimerix is A Company Focused on Infectious Viral Diseases that Has Investment Characteristics Similar to Trius (CMRX, Neutral, $25.48) (Subscribers Only)

Report In Brief
This report is an in-depth analysis of Chimerix (CMRX). I like the fundamental outlook of this company very…
Read more…

SmithOnStocks Mailbox February 25, 2014

I have found that there are some very smart people out there who have interesting questions and perspectives concerning my…
Read more…

The BIO CEO Conference: Highlights from the Meeting and New Investment Perspectives (Subscribers Only)

Back From BIO CEO Conference

I have returned from spending two days at the BIO CEO conference at the Waldorf Astoria…
Read more…

San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)

What SmithOnStocks Is All About
It is traditional at the start of the year to go over stock picks for the…
Read more…

Neuralstem: Sizing Up Potential Key Events of 2014 (CUR, $3.42)

Investment Thesis and Overview
Neuralstemís clinical trial programs and accompanying results for its two key drugs, the neural stem cell product…
Read more…

Neuralstem: Evidence Increasingly Suggests its Neural Stem Cells are Effective in ALS (CUR, $2.57)

Thoughts on the Stock Price
I have been recommending Neuralstem†(CUR) since my initiation report†of November 5, 2012 at a price of…
Read more…

SmithOnStocks Opines on Biotechnology Stocks, June 10, 2013

Introduction
This weekís edition of SmithOnStocks Opines includes brief comments on news concerning ImmunoCellular Therapeutics (IMUC) and Cadence (CADX), last week…
Read more…

SmithOnStocks Opines on Biotechnology Stocks, May 28, 2013

Introduction
I have started to write a newsletter on a weekly or bi-weekly basis to supplement my reports and blogs. In…
Read more…

SmithOnStocks Opines on Stocks May 19, Edition

One Approach for Investing in Emerging Biotechnology Stocks
I write on biotechnology and pharmaceutical companies of all sizes, but I have…
Read more…